RECRUITING

realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL

Description

The realMIND study is a multicenter, observational study intended to further characterize the safety and effectiveness data of US patients (with a focus on racial and ethnic minority patients) with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), treated with tafasitamab in combination with lenalidomide.

Conditions

Diffuse Large B-cell Lymphoma
Talk to us

Related Conditions:

Diffuse Large B-cell Lymphoma

Study Overview

On this page

Study Details

Study overview

The realMIND study is a multicenter, observational study intended to further characterize the safety and effectiveness data of US patients (with a focus on racial and ethnic minority patients) with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), treated with tafasitamab in combination with lenalidomide.

realMIND: A Multicenter, Observational Study to Characterize the Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in US Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma With a Focus on Racial and Ethnic Minority Patients

realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL

Condition
Diffuse Large B-cell Lymphoma
Intervention / Treatment

-

Contacts and Locations

Birmingham

Alabama Oncology, Birmingham, Alabama, United States, 35211

Huntsville

Clearview Cancer Institute, Huntsville, Alabama, United States, 35805

Orange

University of California, Irvine Medical Center, Orange, California, United States, 92868

Ames

McFarland Clinic P.C., Ames, Iowa, United States, 50010

Des Moines

Mission Cancer and Blood, Des Moines, Iowa, United States, 50309

New Orleans

Tulane Cancer Center, New Orleans, Louisiana, United States, 70112

Bethesda

American Oncology Partners of Maryland PA, Bethesda, Maryland, United States, 20817

Ann Arbor

University of Michigan Comprehensive Cancer Center Michigan Medicine, Ann Arbor, Michigan, United States, 48109

Detroit

Henry Ford Health System, Detroit, Michigan, United States, 48202

Morristown

Morristown Medical Center, Morristown, New Jersey, United States, 07960-6136

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Age ≥18 years at the time of diagnosis of R/R DLBCL
  • 2. Initiated or initiating tafasitamab treatment
  • 3. R/R DLBCL patients who have received at least one (1) prior line of treatment for DLBCL
  • 4. Histologically confirmed DLBCL such as:
  • 5. Signed and dated ICF by the patient or the patient's Legally Acceptable Representative (LAR), for patients with prospective data collection, as applicable. For deceased or otherwise unreachable patients, no informed consent will be obtained for data collection in the study, provided that the competent Independent Ethics Committee (IEC)/Institutional Review Board (IRB) has provided favorable opinion and that any other local regulatory requirements on this matter are met

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Incyte Corporation,

John P Galvin, MD, STUDY_DIRECTOR, Incyte Corporation

Study Record Dates

2026-08-31